Literature DB >> 27906745

Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Caroline C Marrs1, Maged M Costantine.   

Abstract

Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27906745      PMCID: PMC5250542          DOI: 10.1097/GRF.0000000000000248

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  48 in total

1.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  The transfer of pravastatin in the dually perfused human placenta.

Authors:  J Zarek; M K DeGorter; A Lubetsky; R B Kim; C A Laskin; H Berger; G Koren
Journal:  Placenta       Date:  2013-06-05       Impact factor: 3.481

3.  Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.

Authors:  Stéphanie Roberge; Baha Sibai; Affette McCaw-Binns; Emmanuel Bujold
Journal:  Am J Perinatol       Date:  2016-02-23       Impact factor: 1.862

Review 4.  Redefining preeclampsia using placenta-derived biomarkers.

Authors:  Anne Cathrine Staff; Samantha J Benton; Peter von Dadelszen; James M Roberts; Robert N Taylor; Robert W Powers; D Stephen Charnock-Jones; Christopher W G Redman
Journal:  Hypertension       Date:  2013-03-04       Impact factor: 10.190

5.  Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement.

Authors:  Michael L LeFevre
Journal:  Ann Intern Med       Date:  2014-12-02       Impact factor: 25.391

Review 6.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

7.  Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.

Authors:  Antonio F Saad; Talar Kechichian; Huaizhi Yin; Elena Sbrana; Monica Longo; Michael Wen; Esther Tamayo; Gary D V Hankins; George R Saade; Maged M Costantine
Journal:  Reprod Sci       Date:  2013-06-07       Impact factor: 3.060

8.  A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States.

Authors:  Erika F Werner; Alisse K Hauspurg; Dwight J Rouse
Journal:  Obstet Gynecol       Date:  2015-12       Impact factor: 7.661

9.  Statins and congenital malformations: cohort study.

Authors:  Brian T Bateman; Sonia Hernandez-Diaz; Michael A Fischer; Ellen W Seely; Jeffrey L Ecker; Jessica M Franklin; Rishi J Desai; Cora Allen-Coleman; Helen Mogun; Jerry Avorn; Krista F Huybrechts
Journal:  BMJ       Date:  2015-03-17

Review 10.  Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.

Authors:  Lisa M Askie; Lelia Duley; David J Henderson-Smart; Lesley A Stewart
Journal:  Lancet       Date:  2007-05-26       Impact factor: 79.321

View more
  6 in total

Review 1.  Challenges in conducting clinical research studies in pregnant women.

Authors:  Monique McKiever; Heather Frey; Maged M Costantine
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-04-18       Impact factor: 2.745

2.  Dyslipidemia and the role of adipose tissue in early pregnancy in the BPH/5 mouse model for preeclampsia.

Authors:  Dorien Reijnders; Kelsey N Olson; Chin-Chi Liu; Kalie F Beckers; Sujoy Ghosh; Leanne M Redman; Jenny L Sones
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-04-17       Impact factor: 3.619

3.  Cell-free DNA Methylation and Transcriptomic Signature Prediction of Pregnancies with Adverse Outcomes.

Authors:  Giorgia Del Vecchio; Qingjiao Li; Wenyuan Li; Shanthie Thamotharan; Anela Tosevska; Marco Morselli; Kyunghyun Sung; Carla Janzen; Xianghong Zhou; Matteo Pellegrini; Sherin U Devaskar
Journal:  Epigenetics       Date:  2020-10-13       Impact factor: 4.528

4.  Involvement of the oncogene B-cell lymphoma 6 in the fusion and differentiation process of trophoblastic cells of the placenta.

Authors:  Britta Jasmer; Cornelia Muschol-Steinmetz; Nina-Naomi Kreis; Alexandra Friemel; Ulrikke Kielland-Kaisen; Dörthe Brüggmann; Lukas Jennewein; Roman Allert; Christine Solbach; Juping Yuan; Frank Louwen
Journal:  Oncotarget       Date:  2017-08-24

Review 5.  Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring.

Authors:  Rachael Fox; Jamie Kitt; Paul Leeson; Christina Y L Aye; Adam J Lewandowski
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

6.  The Function of Oncogene B-Cell Lymphoma 6 in the Regulation of the Migration and Invasion of Trophoblastic Cells.

Authors:  Andreas Ritter; Babek Khan Safdar; Britta Jasmer; Nina-Naomi Kreis; Alexandra Friemel; Susanne Roth; Christine Solbach; Frank Louwen; Juping Yuan
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.